Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Archive ouverte

Vigouroux, Stéphane | Michallet, Mauricette | Porcher, Raphaël | Attal, Michel | Ades, Lionel | Bernard, Marc | Blaise, Didier | Tabrizi, Reza | Garban, Frédéric | Cassuto, Jill-Patrice | Chevalier, Patrice | Facon, Thierry | Ifrah, Norbert | Renaud, Marc | Tilly, Hervé | Vernant, Jean-Paul | Kuentz, Mathieu | Bourhis, Jean-Henri | Bordigoni, Pierre | Deconinck, Eric | Lioure, Bruno | Socié, Gérard | Milpied, Noël, N.

Edité par CCSD ; Ferrata Storti Foundation -

International audience. BACKGROUND AND OBJECTIVES: High-dose chemotherapy with allogeneic stem cell transplantation (SCT) has proven to be a successful treatment for low-grade lymphoma (LGL), but is associated with considerable transplant-related mortality (TRM). In an effort to reduce toxic mortality while maintaining the graft-versus-leukemia effect, allogeneic SCT has been combined with a reduced-intensity conditioning (RIC) regimen. The aim of this study was to determine the outcome of patients with LGL treated with RIC allogeneic SCT. DESIGN AND METHODS: This retrospective multicenter study included 73 patients with relapsed or refractory LGL allografted after a RIC regimen between 1998 and 2005 whose data were recorded in a French registry. RESULTS: Patients received a median of three lines of therapy prior to RIC allogeneic SCT. The most widely used conditioning regimens were fludarabine + busulfan + antithymocyte globulin (n=43) and fludarabine + total body irradiation (n=21). Prior to allografting, patients were in complete response (CR; n=21), partial response (PR; n=33) or had chemoresistant disease (n=19). The median follow-up was 37 months (range, 16 to 77 months). In patients in CR, PR and chemoresistant disease, the 3-year overall survival rates were 66%, 64% and 32%, respectively, while the 3-year event-free survival rates were 66%, 52% and 32%, respectively. The 3-year cumulative incidences of TRM were 32%, 28% and 63%, respectively. The incidence of relapse was 9.6%. INTERPRETATION AND CONCLUSIONS: Although associated with significant TRM, RIC allogeneic SCT in advanced chemosensitive disease leads to long-term survival.

Suggestions

Du même auteur

Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC.

Archive ouverte | Chevallier, Patrice | CCSD

International audience. PURPOSE: This retrospective multicenter study assessed the outcome of 51 patients with myeloid sarcoma (MS) who underwent allogeneic hematopoietic stem-cell transplantation (alloHSCT). PATIEN...

Double umbilical cord blood transplantation for hematological malignancies: a long- term analysis from the SFGM-TC registry.

Archive ouverte | Wallet, Hélène Labussière | CCSD

International audience. : Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for many hematological malignancies for which umbilical cord blood (UCB) represents an alternative source o...

Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Archive ouverte | Michallet, Mauricette | CCSD

International audience. This retrospective study analyzed the impact of demographic and transplantation variables on outcomes of 1108 patients who have undergone allogeneic hematopoietic stem cell transplantation af...

Chargement des enrichissements...